20 years of Cure Parkinson's
We’re here for the cure! This year marks 20 years since Cure Parkinson’s was founded by four people living with Parkinson’s who felt that nobody was taking a cure seriously enough and that there was an urgent need for a focused approach to curative research...
Learn more
Drug repurposing for Parkinson’s – No Silver Bullet 4 Parkinson’s webinar
Cure Parkinson’s funded researcher Dr Lorraine Kalia will be presenting the NoSilverBullet4PD webinar this September discussing ‘Drug repurposing for PD therapies’.
Preliminary phase 2 trial results of lixisenatide presented
A one-year, phase 2 clinical trial of Type 2 diabetes drug lixisenatide has reported positive early results, which indicate that the treatment may slow the progression of motor (or movement) symptoms. Preliminary results of the LixiPark study were presented at the International Parkinson and Movement…
Aspen starts phase 1 stem cell transplant clinical trial
An experimental treatment for Parkinson’s involves the replacement of the lost dopamine neurons by transplanting new cells into the brain. Biotech company Aspen Neuroscience will soon be starting a clinical trial in the US exploring this potential therapy in people with Parkinson’s.
Helen Matthews takes the helm as new CEO of Cure Parkinson’s
10 August 2023 We are delighted to announce that Helen Matthews will be taking over as CEO of Cure Parkinson’s later this summer. As our current Deputy CEO and former COO, Helen has been a driving force behind the charity since it was formed over…
Rallying to the Challenge 2023: recorded to watch again
Rallying to the Challenge is a meeting designed for and by people with Parkinson’s, advocates and care partners to explore how the Parkinson’s community can impact and accelerate research.